![Loading...](https://link.springer.com/static/c4a417b97a76cc2980e3c25e2271af3129e08bbe/images/pdf-preview/spacer.gif)
-
Article
Gender differences in non-motor symptoms in early, drug naïve Parkinson’s disease
Gender differences in brain structure and function may lead to differences in the clinical expression of neurological diseases, including Parkinson’s disease (PD). Few studies reported gender-related differenc...
-
Article
Insulin-like growth factor-1 and progression of motor symptoms in early, drug-naïve Parkinson’s disease
Much pre-clinical evidence show that insulin-like growth factor 1 (IGF-1) provides protection against loss of dopaminergic neurons. Recently, IGF-1 has been proposed as a possible biomarker for early diagnosis...
-
Article
Serum epidermal growth factor predicts cognitive functions in early, drug-naive Parkinson’s disease patients
Epidermal growth factor (EGF) has been proposed as a candidate biomarker for cognitive impairment in Parkinson’s disease (PD). We aimed to assess the relationship between serum EGF and cognitive functions in e...